[go: up one dir, main page]

DK2917231T3 - Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme - Google Patents

Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme Download PDF

Info

Publication number
DK2917231T3
DK2917231T3 DK13796020.9T DK13796020T DK2917231T3 DK 2917231 T3 DK2917231 T3 DK 2917231T3 DK 13796020 T DK13796020 T DK 13796020T DK 2917231 T3 DK2917231 T3 DK 2917231T3
Authority
DK
Denmark
Prior art keywords
diseases
lipopeptides
treatment
liver
cardiovascular
Prior art date
Application number
DK13796020.9T
Other languages
English (en)
Inventor
Volker Cleeves
Ralf Kubitz
Stephan Urban
Original Assignee
Univ Heidelberg Ruprecht Karls
Volker Cleeves
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Heidelberg Ruprecht Karls, Volker Cleeves filed Critical Univ Heidelberg Ruprecht Karls
Application granted granted Critical
Publication of DK2917231T3 publication Critical patent/DK2917231T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067Liver cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DK13796020.9T 2012-11-12 2013-11-12 Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme DK2917231T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725144P 2012-11-12 2012-11-12
US201361859476P 2013-07-29 2013-07-29
PCT/EP2013/073600 WO2014072524A1 (en) 2012-11-12 2013-11-12 Lipopetides for use in treating liver diseases and cardiovascular diseases

Publications (1)

Publication Number Publication Date
DK2917231T3 true DK2917231T3 (da) 2019-06-11

Family

ID=49674268

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13796020.9T DK2917231T3 (da) 2012-11-12 2013-11-12 Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme

Country Status (8)

Country Link
US (4) US10413585B2 (da)
EP (1) EP2917231B1 (da)
CN (2) CN104781274B (da)
DK (1) DK2917231T3 (da)
ES (1) ES2728243T3 (da)
HK (1) HK1214274A1 (da)
PL (1) PL2917231T3 (da)
WO (1) WO2014072524A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015014830A1 (en) * 2013-07-29 2015-02-05 Rupprecht-Karls-Universität Heidelberg Lipopetides for use in treating liver diseases and cardiovascular diseases
CN106794188B (zh) 2014-09-28 2022-12-02 华辉安健(北京)生物科技有限公司 聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
KR102599942B1 (ko) * 2014-10-07 2023-11-09 엠와이알 게엠베하 Hbv 및 hdv 감염의 조합 치료법
US10482551B2 (en) * 2015-08-10 2019-11-19 Google Llc Systems and methods of automatically estimating restaurant wait times using wearable devices
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
EP3189850A1 (en) 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Liver targeting of cyclic pres-derived peptides of hbv
EP3463422B1 (en) * 2016-05-30 2024-05-22 Shanghai Hep Pharmaceutical Co., Ltd. Compositions and methods for treating metabolic diseases
US10366219B2 (en) 2016-11-16 2019-07-30 Bank Of America Corporation Preventing unauthorized access to secured information using identification techniques
US10474800B2 (en) 2016-11-16 2019-11-12 Bank Of America Corporation Generating alerts based on vehicle system privacy mode
CN106749551A (zh) * 2016-12-30 2017-05-31 吉林大学 一种以多表位肽段组合抗原刺激免疫系统产生抗体的方法
EP3804750A1 (en) 2019-10-10 2021-04-14 Universität Heidelberg Conjugate compounds for preventing and/or treating hbv and/or hdv infections, liver diseases and for targeting ntcp
CN111574594A (zh) * 2020-05-26 2020-08-25 成都圣诺生物制药有限公司 一种Bulevirtide的制备方法
WO2025031397A1 (zh) * 2023-08-08 2025-02-13 前沿生物药业(南京)股份有限公司 钠离子-牛磺胆酸共转运蛋白长效抑制剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2847288T3 (es) * 2008-01-25 2021-08-02 Univ Heidelberg Ruprecht Karls Péptidos derivados de preS hidrófobos modificados del virus de la hepatitis B (VHB) y su uso como vehículos para el suministro específico de compuestos al hígado
WO2009092396A1 (en) 2008-01-25 2009-07-30 Universitätsklinikum Heidelberg Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors
CN101240014B (zh) * 2008-03-07 2011-01-26 山东省科学院生物研究所 一种具有生理活性的脂肽复合物及其制备方法与应用
JP6486004B2 (ja) 2011-02-10 2019-03-20 ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクRuprecht−Karls−Universitaet Heidelberg 疎水性修飾ペプチドおよび肝臓特異的標的化のためのその使用
CN109354623B (zh) * 2012-04-25 2022-06-24 华辉安健(北京)生物科技有限公司 乙肝肝炎病毒功能性受体的组成以及相关应用

Also Published As

Publication number Publication date
EP2917231A1 (en) 2015-09-16
US20240123025A1 (en) 2024-04-18
EP2917231B1 (en) 2019-03-06
ES2728243T3 (es) 2019-10-23
CN111499722A (zh) 2020-08-07
US20160015775A1 (en) 2016-01-21
CN111499722B (zh) 2024-08-23
CN104781274B (zh) 2020-03-06
WO2014072524A1 (en) 2014-05-15
US10413585B2 (en) 2019-09-17
US20190151406A1 (en) 2019-05-23
CN104781274A (zh) 2015-07-15
US20200384070A1 (en) 2020-12-10
US10967044B2 (en) 2021-04-06
PL2917231T3 (pl) 2019-08-30
HK1214274A1 (zh) 2016-07-22

Similar Documents

Publication Publication Date Title
DK2917231T3 (da) Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme
DK3444342T3 (da) Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
DK3838923T3 (da) Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hæmning af metastase
DK3378862T3 (da) Dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af multipel sklerose
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2804587T3 (da) Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
DK2818481T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
DK2900061T3 (da) Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
DK3444261T3 (da) 2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser
DK2774616T3 (da) Anvendelse af roseburia i behandling og forebyggelse af fedmerelaterede sygdomme
DK3335709T3 (da) Gamma-hydroxybutyratsammensætninger og deres anvendelse til behandling af lidelser
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK2776567T3 (da) Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK3400944T3 (da) Ibat-inhibitorer til behandling af leversygdomme
CO6811815A2 (es) Composiciones de nucleasa terapéuticas y métodos
DK2704703T3 (da) Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf
DK2909196T3 (da) Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK2701693T3 (da) Tapentadol til hindring og behandling af depression og angst
DK2688557T3 (da) Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
DK2909197T3 (da) Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi
DK2882441T3 (da) Behandling af immunrelaterede og inflammatoriske sygdomme